HFA Premium Access

Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry

Congress Presentation

About the speaker

Miss Federica Guidetti

Karolinska Institute, Stockholm (Sweden)
0 follower

6 more presentations in this session

Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Speaker: Doctor D. Stolfo (Trieste, IT)


Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

Speaker: Doctor S. Chatur (Boston, US)


Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.

Speaker: Doctor J. Tromp (Singapore, SG)


Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure

Speaker: Ms I. Beldhuis (Groningen, NL)


Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial

Speaker: Doctor M. Senni (Bergamo, IT)


Access the full session


Speakers: Miss F. Guidetti, Doctor D. Stolfo, Doctor S. Chatur, Doctor J. Tromp, Ms I. Beldhuis...

About the event


Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

ESC 365 is supported by